¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"Metabolic Detoxication, Phase I"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • metabolic disorder
    ´ë»çÀå¾Ö
  • metabolic equilibrium
    ´ë»çÆòÇü
  • metabolic error
    ´ë»çÀÌ»ó
  • metabolic imbalance
    ´ë»çºÒ±ÕÇü
  • metabolic inhibitor
    ´ë»ç¾ïÁ¦Á¦
  • metabolic map
    ´ë»ç°æ·Îµµ
  • metabolic monitoring
    ´ë»ç·®Á¶»ç
  • metabolic network
    ´ë»ç¸Á, ´ë»ç±×¹°
  • metabolic pathway
    ´ë»ç°æ·Î
  • metabolic rate
    ´ë»çÀ²
  • metabolic regulation
    ´ë»çÁ¶Àý
  • metabolic water
    ´ë»ç¼ö
  • relative metabolic rate
    »ó´ë´ë»çÀ²
  • somnolent metabolic rate
    ¼ö¸é´ë»çÀ²
  • acceleration phase
    ÃËÁø±â, °¡¼Ó±â
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 11 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • latent phase
    ÀáÀç±â , Àẹ±â
  • plateau phase
    ÆíÆò±â, °íÁ¶±â
  • relaxation phase
    À̿ϱâ, À̿ϻó
  • resolution phase
    ÇØ¼Ò±â
  • resting phase
    È޽ıâ
  • solid phase
    °íü»ó
  • stance phase
    µðµõ±â, ÀÔ°¢±â
  • swing phase
    Èçµê±â, À¯°¢±â
  • synaptic phase
    ¿¬Á¢±â
  • expiratory phase time
    ³¯¼û½Ã°£, È£±â½Ã°£
  • inspiratory phase time
    µé¼û½Ã°£, Èí±â½Ã°£
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • metabolic equilibrium
    ´ë»çÆòÇü
  • metabolic error
    ´ë»çÀÌ»ó
  • metabolic hypothesis
    ´ë»ç°¡¼³
  • metabolic imbalance
    ´ë»çºÒ±ÕÇü
  • metabolic inhibitor
    ´ë»ç¾ïÁ¦Á¦
  • metabolic
    ´ë»ç-
  • metabolic map
    ´ë»ç°æ·Îµµ
  • metabolic monitoring
    ´ë»ç·®Á¶»ç
  • metabolic network
    ´ë»ç¸Á
  • metabolic pathway
    ´ë»ç°æ·Î
  • metabolic rate
    ´ë»çÀ²
  • metabolic regulation
    ´ë»çÁ¶Àý
  • metabolic tolerance
    ´ë»ç³»¼º
  • metabolic turnover
    ´ë»çÀüȯ
  • metabolic water
    ´ë»ç¼ö
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • anal-sadistic phase
    Ç×¹®-°¡ÇÐ(½Ã)±â
  • arterial phase
    µ¿¸Æ±â
  • full erection phase
    ¿ÏÀü¹ß±â±â
  • g0 phase
    Á¤Áö±â G0±â
  • g1 phase
    ÇÕ¼ºÀü±â G1±â
  • g2 phase
    ÇÕ¼ºÈıâ G2±â
  • gastric phase
    À§»ó(êÖßÓ) À§»êºÐºñ(êÖߤÝÂÝô)ÀÇ .
  • go phase
    Á¤Áö±â Go±â
  • gradient induced phase shift effect
    °æ»ç À¯µµ À§»ó º¯À§ È¿°ú
  • grinding phase
    ºÐ¼â»ó.
  • implantational phase
    Âø»ó±â
  • in-phase image
    À§»ó³» ¿µ»ó
  • inactive phase
    ºñȰµ¿±â
  • inadequate luteal phase
    Ȳü±âºÎÀü(üÜô÷ÐïÝÕîï).
  • inadequate luteal phase
    Ȳü±âºÎÀü(üÜô÷ÐïÝÕîï).
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • metabolic acidemia
    ´ë»ç¼º»êÇ÷Áõ
  • metabolic acidosis
    ´ë»ç¼º »êÁõ, ´ë»ç¼º ¾Æ ½Ãµµ½Ã½º.
  • metabolic acidosis
    ´ë»ç¼º ½ÅÁõ(ÓÛÞóàõ ãìñø)
  • metabolic acidosis
    ´ë»ç¼º»êÁõ
  • metabolic alkalemia
    ´ë»ç¼º¾ËÄ«¸®Ç÷Áõ
  • metabolic alkalosis
    ´ë»ç¼º ¾ËÄ®¸®Áõ.
  • metabolic alkalosis
    ´ë»ç¼º ¿°±âÁõ
  • metabolic alkalosis
    ´ë»ç¼º¾ËÄ«¸®Áõ
  • metabolic analogue
    ´ë»çÀû À¯»ç¹°Áú.
  • metabolic antagonism
    ´ë»ç±æÇ×(¡­ÑÏù÷).
  • metabolic antagonist
    ´ë»ç±æÇ×Á¦(¡­ÑÏù÷ð¥).
  • metabolic chemistry
    ´ë»çÈ­ÇÐ.
  • metabolic clearance rate =MCR
    ´ë»çŬ¸®¾î·±½ºÀ².
  • metabolic clock
    ´ë»çÀÛ¿ëÀÇ ½Ã°£Àû ¸®µë.
  • metabolic craniopathy
    ´ë»ç¼º µÎ°³Àå¾Ö(¡­ÔéËÏî¡äô).
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • Phase of desquamation
    ¹Ú¸®±â
    [¿¾ ¿ë¾î] ¹Ú¸®±â
  • Phase of incornification
    ºñ°¢Áú±â
    [¿¾ ¿ë¾î] ºñ°¢ÁúÈ­±â
  • Unequal phase
    ºñ´ëαâ
    [¿¾ ¿ë¾î] ºÎµî»ó
  • Inactive phase
    ºñȰµ¿±â
    [¿¾ ¿ë¾î] ÈÞÁö±â
  • Lactiferous phase
    ¼öÀ¯±â
    [¿¾ ¿ë¾î] ¼öÀ¯±â
  • Synaptic phase
    ¿¬Á¢±â
    [¿¾ ¿ë¾î] ¿¬Á¢±â
  • Menstrual phase
    ¿ù°æ±â
    [¿¾ ¿ë¾î] ¿ù°æ±â
  • Postmenstrual phase
    ¿ù°æÈıâ
    [¿¾ ¿ë¾î] ¿ù°æÈıâ
  • Zygotene phase
    Á¢ÇÕ±â
    [¿¾ ¿ë¾î] Á¢ÇÕ±â
  • Go phase
    Á¤Áö±â [Go±â]
    [¿¾ ¿ë¾î] Á¤Áö±â
  • Proliferative phase
    Áõ½Ä±â
    [¿¾ ¿ë¾î] Áõ½Ä±â
  • Implantational phase
    Âø»ó±â
    [¿¾ ¿ë¾î] Âø»ó±â
  • Preimplantational phase
    Âø»óÀü±â
    [¿¾ ¿ë¾î] Âø»óÀü±â
  • Colostral phase
    ÃÊÀ¯±â
    [¿¾ ¿ë¾î] ÃÊÀ¯±â
  • Placental phase
    Źݱâ
    [¿¾ ¿ë¾î] Źݱâ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • metabolic disease
    ´ë»çÁúȯ(ÓÛÞóòðü´)
  • metabolic pathway
    ´ë»ç °æ·Î(ÓÛÞóÌèÖØ)
  • metabolic poison
    ´ë»ç µ¶(ÓÛÞóÔ¸)
  • metabolic pool
    ´ë»ç(ÓÛÞó) Ç®
  • metabolic quotient
    ´ë»ç»ó(ÓÛÞóßÂ)
  • metabolic shunt
    ´ë»ç ºÐ·Î(ÓÛÞóÝÂÖØ)
  • metabolic transformation
    ´ë»ç º¯Çü(ÓÛÞóܨû¡)
  • metabolic turnover
    ´ë»ç ÀüÈ­(ÓÛÞóï®ûù)
  • reversible metabolic pathway
    °¡¿ª ´ë»ç°æ·Î(ÓÛÞóÌèÖØ)
  • tiered metabolic pathway
    ÃþÃþ´ë»ç °æ·Î (öµöµÓÛÞóÌèÖØ)
  • aqueous phase separator centrifugation
    ¾×»ó ºÐ¸®Ã¼ ¿ø½ÉºÐ¸® (äûßÒ ÝÂ×îô÷ êÀãýÝÂ×î)
  • carboxylation phase
    Ä«¸£º¹½ÇÈ­(ûù)±â(Ñ¢)
  • death phase
    »ç¸ê±â(ÞÝØþÑ¢)
  • decline phase
    "°¨Åð±â(Êõ÷ÜÑ¢), (ÔÒ) death phase"
  • effective lethal phase
    À¯È¿ Ä¡»ç±â(êóüùöÈÞÝÑ¢)
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • intravoxel phase dispersion
    º¹¼¿³»À§»óÈ®»ê
  • out of phase
    Å»À§»óÀÇ
  • out of phase gradient echo image
    Å»À§»ó°æ»ç¿¡ÄÚ¿µ»ó
  • phase
    ȗ, ˤȗ
  • phase angle
    À§»ó°¢
  • phase artifact
    À§»óÀΰø¹°
  • phase axis
    ˤȗ̈
  • phase cancellation artifact
    À§»ó¸»¼Ò(»ó¼â)Àΰø¹°
  • phase coherence
    À§»ó°áÁý
  • phase conjugate symmetry
    À§»óȸº¹´ëĪ, À§»ó°ø¾×´ëĪ
  • phase contrast
    À§»ó´ëÁ¶
  • phase contrast MR angiography
    À§»ó´ëÁ¶ÀÚ±â°ø¸íÇ÷°üÁ¶¿µ¼ú
  • phase curve
    À§»ó°î¼±
  • phase display
    À§»óÇ¥½Ã
  • phase encode direction
    À§»óºÎȣȭ¹æÇâ
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
RMR Resting Metabolic Rate
  = Resting Energy Expenditure
ADMR average daily metabolic rate
AMR acoustic muscle reflex; activity metabolic rate; acute mitral stenosis; alopecia-mental retardation ...
BMR basal metabolic rate
BMU basic metabolic unit; basic multicellular unit
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
CMRglc Cerebral metabolic rate for glucose
CMRO2 Cerebral metabolic rate for oxygen
CMRO2 Cerebral metabolic rate of oxygen
CMA Chronic metabolic acidosis
FMR Field metabolic rate
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • metabolic rate
    ´ë»çÀ²
  • metabolic waste product
    ´ë»ç ³ëÆó¹°, ´ë»ç »ê¹°
  • accelerated death phase
    °¡¼Ó »ç¸ê±â
  • acceleration phase
    ÃËÁø±â, °¡¼Ó±â
    ¹Ì»ý¹° ¹è¾ç ½Ã °©Àڱ⠼ºÀåÀÌ Áõ°¡ÇÏ´Â ½Ã±â.
  • acute phase protein
    ±Þ¼º±â ´Ü¹éÁú
    °¨¿°À̳ª Á¶Á÷ ¼Õ»óÀÌ ÀÖÀ» ¶§ Á¤»óº¸´Ù 2-100¹è Á¤µµ Áõ°¡ÇÏ´Â Ç÷Àå ´Ü¹éÁúÀ» ÃÑĪÇÏ¿© APP¶ó°í ÇÏ¸ç ¼±Ãµ¼º ¸é¿ª¿¡ °ü¿©ÇÑ´Ù.
  • acute phase reaction
    ±Þ¼º±â ¹ÝÀÀ
  • acute phase serum
    ±Þ¼º º´±â Ç÷û
  • anal-sadistic phase
    Ç×¹®-°¡Çбâ, Ç×¹®-°¡ÇÐ ½Ã±â
  • arousal phase
    ÀáÀ» ±ú´Â ½Ã±â
  • arterial phase
    µ¿¸Æ ±â
  • bacterial phase
    ¼¼±Õ »ó
    ¼¼±ÕÀÌ ´«¿¡ º¸ÀÌ´Â ¾ç»ó.
  • closing phase
    Æó±¸ ´Ü°è
  • dispersed phase
    ºÐ»ê »ó
  • equilibrium phase diagram
    ÆòÇü »óŵµ
    ÇÕ±ÝÀÇ Á¶¼º°ú ¿Âµµ°¡ ¹Ù²î¾îÁ³À» ¶§ÀÇ ÆòÇü »óÅ¿¡¼­ÀÇ »óÀÇ º¯È­¸¦ º¸ÀÎ ±×¸².
  • expiratory phase
    È£±â
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
metabolic craniopathy <syndrome> Hyperostosis frontalis interna in elderly women, with obesity and neuropsychiatric disorders of uncertain cause; at least sometimes familial.
Synonym: metabolic craniopathy, Stewart-Morel syndrome.
(05 Mar 2000)
metabolic disease Generic term for diseases caused by an abnormal metabolic process. It can be congenital due to inherited enzyme abnormality (metabolism, inborn errors) or acquired due to disease of an endocrine organ or failure of a metabolically important organ such as the liver.
(12 Dec 1998)
metabolic encephalopathy Encephalopathy characterised by memory loss, vertigo, and generalised weakness, due to metabolic brain disease including hypoxia, ischemia, hypoglycaemia, or secondary to other organ failure such as liver or kidney.
(05 Mar 2000)
metabolic equivalent The oxygen cost of energy expenditure measured at supine rest (1 MET = 3.5 ml O2 per kg of body weight per minute); multiples of MET are used to estimate the oxygen cost of activity, e.g., 3 to 5 METs for light work; more than 9 METs for heavy work.
(05 Mar 2000)
metabolic indican 1. <chemistry> A glucoside obtained from woad (indigo plant) and other plants, as a yellow or light brown sirup. It has a nauseous bitter taste, a decomposes or drying. By the action of acids, ferments, etc, it breaks down into sugar and indigo. It is the source of natural indigo.
2. <physiology> An indigo-forming substance, found in urine, and other animal fluids, and convertible into red and blue indigo (urrhodin and uroglaucin). Chemically, it is indoxyl sulphate of potash, C8H6NSO4K, and is derived from the indol formed in the alimentary canal.
Synonym: uroxanthin.
See: Indigo.
Source: Websters Dictionary
(01 Mar 1998)
metabolic mucinosis Diffuse or pretibial myxoedema, lichen myxoedematosus, gargoylism, secondary mucinosis, degeneration in tumours, localised mucinosis, follicular, papular, plaque-like, focal, and myxoid or synovial cyst.
Origin: mucin + G. -osis, condition
(05 Mar 2000)
metabolic pool The quantity of a given chemical compound or group of related compounds participating in metabolic reactions; may constitute only a portion of the total bodily content of such compounds.
(05 Mar 2000)
compensated metabolic alkalosis The retention of acid, primarily carbon dioxide by the lung and acid ions by the renal tubules, to reduce the effect on the pH of the blood of excess alkali produced by ingestion or metabolism of alkali-producing substances.
(05 Mar 2000)
skin diseases, metabolic Diseases of the skin associated with underlying metabolic disorders.
(12 Dec 1998)
steroid metabolic clearance rate A measure of the rate of metabolism of a given steroid within the body, usually expressed as liters of body fluid that contain the amount of steroid metabolised per day.
(05 Mar 2000)
nutritional and metabolic diseases A collective term for nutritional disorders (result of poor assimilation or utilization of food) and metabolic disorders (result of poor metabolism or inherited enzyme abnormality).
(12 Dec 1998)
accelerated phase of leukaemia Refers to chronic myelogenous leukaemia that is progressing. The number of immature, abnormal white blood cells in the bone marrow and blood is higher than in the chronic phase, but not as high as in the blast phase.
(12 Dec 1998)
acceleration phase <cell biology, cell culture> A period of increasing growth before the log phase in a culture of microbes.
After the culture is started on a medium, at first there is no growth (the lag phase) and then the microbes start to gradually grow (acceleration phase) until they reach a constant maximum rate of growth (log phase).
(15 Jan 1998)
acute-phase protein <haematology> These plasma proteins (in addition to fibrinogen) increase 25% or more in response to inflammation and injury are under direct control of interleukin-6 (IL-6) (hepatocyte-stimulating factor).
Other proteins which increase are ceruloplasmin, C3 and C4 which increase 50% or more; alpha-1 acid glycoprotein, alpha-1 antitrypsin, haptoglobin and fibrinogen (the major determinant of viscosity 1 ) which increase two- to fourfold; C-reactive protein (CRP) and serum amyloid A which increase several hundred-fold.
Despite long-held clinical opinion to the contrary, available data indicate that neither ESR nor measurement of specific acute-phase reactants are useful in excluding underlying infection or inflammation regardless of the pretest probability.
These proteins are secreted into the blood in increased or decreased quantities by hepatocytes in response to trauma, inflammation, or disease. They can serve as inhibitors or mediators of the inflammatory processes. Certain acute-phase proteins have been used to diagnose and follow the course of diseases or as tumour markers.
See also: amyloid, c-reactive protein, erythrocyte sedimentation rate, viscosity.
(25 Jun 1999)
acute-phase reaction <immunology, rheumatology> Refers to the changes in synthesis of certain proteins within the serum during an inflammatory response, which provides rapid protection for the host against microorganisms via non-specific defense mechanisms.
It consists of fever, an increase in inflammatory humoral factors, and an increased synthesis by hepatocytes of a number of proteins or glycoproteins usually found in the plasma; the reaction is mediated by endogenous pyrogens, the hypothalamus, adrenal hormones, and other factors.
(12 Jul 2000)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
ÅëÇÕ°Ë»ö ¿Ï·á